期刊文献+

血栓弹力图检测老年冠心病患者经皮冠状动脉介入治疗后血小板反应性 被引量:4

Evaluation of platelet reactivity by thromboelastogram in elderly patients after percutaneous coronary intervention
暂未订购
导出
摘要 目的探讨经皮冠状动脉介入治疗术后,经血栓弹力图检测的氯吡格雷药物抵抗患者,不同药物剂量治疗下血小板反应性。方法筛选120例阿司匹林抑制良好而氯吡格雷抑制不敏感的患者,随机分为试验组(60例)和对照组(60例),对照组每天服用100 mg阿司匹林及75 mg氯吡格雷,试验组服用100 mg阿司匹林及150 mg氯吡格雷,检测6个月后氯吡格雷的作用效果,观察2组间6个月内心血管事件及出血事件的发生率。结果试验组心血管死亡、支架内血栓形成、不稳定性心绞痛、心肌梗死发生率分别为0,8.3%,21.7%,8.3%;对照组分别为3.3%,18.3%,35.0%,15.0%,试验组患者氯吡格雷药物抑制率较对照组明显升高(65.6±5.1)% vs (40.9±7.3)%,差异有统计学意义(P<0.01)。结论对于血小板高反应性老年患者,每天75 mg氯吡格雷不能满足血小板抑制效果,长期加倍剂量服用能够在一定程度上有效减低药物抵抗发生率,改善血小板抑制效果,从而降低心血管缺血事件的发生率。 Objective To investigate platelet reactivity measured by thromboelastogram in patients with clopidogrel resistance treated with different dosages of the drug after percutaneous coronary intervention(PCI). Methods 120 patients who were sensitive to aspirin and not sensitive to clopidogrel were randomly divided into two groups,and given 100 mg aspirin plus 75 mg clopidogrel daily in control group(CON) and 100 mg aspirin plus 150 mg ctopidogrel in test group. A 6-month follow-up was carried out to examine the change of effect of antiplatelet therapy,the incidence of bleeding, and to estimate the relationship between platelet aggregation inhibition rate and the incidence of cardiovascular ischemic events. Results After 6-month antiplatelet therapy,the platelet aggregation inhibition rate of clopidogrel in test group was significantly higher than that in CON group[(65.6±5.1)% vs (40.9±7.3)%, P 〈 0.01]. The incidences of cardiovascular ischemic events including cardiovascular death,in-stent thrombosis,recurrent unstable angina and myocardial infarction in test group were 0,8.3 %,21.7 % and 8.3 %, respectively, decreased significantly as compared with those in CON group(3.3% ,18.3% ,35.0% and 15.0%, P 〈 0.01). Conclusion According to the result of thromboelastograph determinations, daily 75 mg clopidogrel can not reach a satisfactory platelet inhibition effect in patients who were not sensitive to clopidogrel. A maintenance loading dose of antiplatelet therapy with 150 mg clopidogrel daily can decrease the rate of recurrent cardiovascular ischemic events effectively.
机构地区 解放军
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2010年第10期879-881,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 血栓弹力描记术 冠心病 血管成形术 经腔 经皮冠状动脉 血小板聚集抑制剂 血小板活化 thromboelastography coronary disease angioplasty, transluminal, percutaneous coro-nary platelet aggregation inhibitors platelet activation
  • 相关文献

参考文献8

  • 1Gurbel PA,Tantry US.Aspirin and clopidogrel resistance:consideration and management.Journal of Interventional Cardiology,2006,19:439-448.
  • 2司良毅.积极稳妥推进老年冠心病的介入治疗[J].中华老年心脑血管病杂志,2009,11(4):241-242. 被引量:7
  • 3Barragan P,Bouvier JL,Roquebert PO,et al.Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.Cathet Cardiovasc Interv,2003,59:295-302.
  • 4Rivard GE,Brummel-Ziedins KE,Mann KG,et al.Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography.J Thromb Haemost,2005,3:2039-2043.
  • 5Swallow RA,Agarwala RA,Dawkins KD,et al.Thromboelastography:potential bedside tool to assess the effects of antiplatelet therapy? Platelets,2006,7:385-392.
  • 6Gurbel PA,Bliden KP,Guyer K,et al.Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING study.J Am Coll Cardiol,2005,46:1820-1826.
  • 7Shim CY,Yoon SJ,Park S,et al.The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation.Int J Cardiol,2009,134:351-355.
  • 8Oqueli E,Hiseock M,Dick R.Clopidogrel resistance.Heart Lung Circ,2007,16:S17-S28.

二级参考文献7

  • 1Boczkowska-Gaik E, Tendera M, Pathogenesis and treatment of acute coronary syndromes. Wiad lek, 2005,58 : 425-432.
  • 2Ting HH, Yang EH, Rihal CS. Narrative review l reperfusion strategies for ST-segment elevation myocardial infarction. Ann Intern Med, 2006,145 : 610-617.
  • 3Larson DM, Henry TD. Reperfusion options in ST-elevation myocardial infarction patients with expected delays, Curt Cardiol Rep, 2008,10:415-423.
  • 4De la Cruz KI, Tsai PI, Cohn WE, et al. Revascularization treatment recommendations based on atherosclerotic disease distribution:coronary artery bypass grafting versus stenting. Curt Atheroseler Rep, 2008,10 : 434-437.
  • 5Biondi-Zoccai GG, Lotrionte M, Moretti C, et al. A collaboratsystematic anatomy systematic review and meta-analysis on 1278 patients undergiong percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J, 2008,155 : 274-283.
  • 6Zimarino M,Sacchetta D,Renda G,et al. Facilitated PCI, rationale, current evidence, open question,and future directions. J Cardiovasc Pharmacol, 2008,51 : 3-10.
  • 7Cohen M, Diez J, Frv E, et al. Strategies for optimizing outcomes in the NSTE-ACS patient the CATH(cardiac catheterization and antithrombotic therapy in the hospital)Clinical Consensus Panel Report. J Invasive Cardiol, 2006,18:617-639.

共引文献6

同被引文献35

  • 1陈颖,徐培敬,张枫林.冠心病患者血小板活化因子(CD62p、CD63)表达的临床意义[J].中国心血管病研究,2007,5(2):112-113. 被引量:8
  • 2Savi P, Herbert JM. Clopidogrel and ticlopidine : P2Y12 aden- osine diphosphate-reeeptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost, 2005,31 : 174-183.
  • 3Tolleson TR,Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol, 2003,92 : 330-333.
  • 4Geiger J,Brich J, H6nig-Liedl P, et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioseler ThrombVasc Biol, 1999,19:2007-2011.
  • 5Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and elopidogrel. CMAJ, 2009,180 : 713-718.
  • 6De Morais SM, Wilkinson GR, Blaisdell J, et al. The major ge- netic de{eet responsible for the polymorphism of S:mepheny- toin metabolism in humans. J Biol Chem, 1994, 269: 15419 15422.
  • 7Giusti B,Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol, 2009, 103,806-811.
  • 8Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines:Clinical detection of coronary stent thrombo- sis by monitoring vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv, 2003, 59: 295- 302.
  • 9Gurbe| PA, Bliden KP, Guyer patients and recurrent events prepare post-stenting study. J 1820-1826. K, eta|. Piate|et reactivity in post-stenting: Results of the Am Coil Cardiol, 2005, 46:.
  • 10Bonello L, Harhouri K, Sabatier F, et al. Level of adenosine diphosphate receptor P2Y12 blockade during pereutaneous coronary intervention predicts the extent of endothelial inju- ry, assessed by circulating endothelial cell measurement. J Am Coil Cardiol,2010,56 : 1024-1031.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部